Epilepsy

Neurology
209
Pipeline Programs
26
Companies
50
Clinical Trials
1 recruiting
16
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
34
1
52
1
77
44
Early DiscoveryClinical DevelopmentMarket

On Market (16)

Approved therapies currently available

UP
BRIVIACTApproved
brivaracetam
UCB Pharma
oral2016
UP
KEPPRAApproved
levetiracetam
UCB Pharma
intravenous2006
UP
KEPPRA XRApproved
levetiracetam
UCB Pharma
oral2008
U
LAMOTRIGINEApproved
lamotrigine
Unknown Company
Anti-epileptic Agent [EPC]oral2024
U
MOTPOLY XRApproved
lacosamide
Unknown Company
oral2023
U
OXCARBAZEPINEApproved
oxcarbazepine
Unknown Company
Anti-epileptic Agent [EPC]oral2022
U
OXCARBAZEPINE EXTENDED RELEASE TABLETSApproved
oxcarbazepine
Unknown Company
extended release
U
QUDEXY XRApproved
topiramate
Unknown Company
oral2014
U
SPRITAMApproved
levetiracetam
Unknown Company
oral2015
J&
TOPAMAXApproved
topiramate
Johnson & Johnson
oral1996
J&
TOPAMAX SPRINKLEApproved
topiramate
Johnson & Johnson
oral1998
U
TOPIRAMATEApproved
topiramate
Unknown Company
oral2017
Novartis
TRILEPTALApproved
oxcarbazepine
Novartis
Anti-epileptic Agent [EPC]oral2000
UP
VIMPATApproved
lacosamide
UCB Pharma
intravenous2008
U
ZONEGRANApproved
zonisamide
Unknown Company
Anti-epileptic Agent [EPC]oral2000
U
ZONISAMIDEApproved
zonisamide
Unknown Company
Anti-epileptic Agent [EPC]oral2006

Competitive Landscape

23 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
90 programs
5
18
1
48
9
LacosamidePhase 41 trial
LevetiracetamPhase 41 trial
LevetiracetamPhase 41 trial
LevetiracetamPhase 41 trial
LevetiracetamPhase 41 trial
+85 more programs
Active Trials
NCT03532516Available
NCT03517423Completed51Est. Aug 2023
NCT01296880Completed60Est. Jul 2014
+87 more trials
E
EisaiChina - Liaoning
33 programs
7
7
14
PerampanelPhase 41 trial
PerampanelPhase 41 trial
Perampanel 1 week titrationPhase 41 trial
Perampanel Oral TabletPhase 41 trial
ZonegranPhase 41 trial
+28 more programs
Active Trials
NCT03208660Completed2,000Est. Mar 2019
NCT02736162Completed61Est. Jul 2016
NCT00298818Completed25Est. Mar 2008
+30 more trials
NeuroPace
NeuroPaceMOUNTAIN VIEW, CA
9 programs
3
2
1
RNS® SystemPhase 41 trial
RNS® System implantationPhase 31 trial
Responsive stimulationPhase 31 trial
RNS SystemPhase 21 trial
RNS® System implantationPhase 21 trial
+4 more programs
Active Trials
NCT02403843Active Not Recruiting375Est. Jan 2026
NCT04839601Terminated9Est. May 2025
NCT02781129CompletedEst. May 2025
+6 more trials
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
8 programs
3
4
1
TopiramatePhase 41 trial
Topiramate; Carbamazepine; ValproatePhase 31 trial
topiramatePhase 31 trial
topiramatePhase 31 trial
topiramatePhase 31 trial
+3 more programs
Active Trials
NCT00236691Completed188Est. Dec 1990
NCT00236873Completed47Est. May 1993
NCT00236847Completed60Est. Jul 1993
+5 more trials
Abbott
AbbottABBOTT PARK, IL
3 programs
1
Rapid versus slow conversionPhase 41 trial
ComplianceN/A1 trial
DivalproexN/A1 trial
Active Trials
NCT00356018Completed5Est. May 2007
NCT00347152Completed18Est. Dec 2007
NCT00312676Unknown20Est. Oct 2006
Sanofi
SanofiPARIS, France
2 programs
1
valproate microgranulesPhase 41 trial
Sodium valporateN/A1 trial
Active Trials
NCT06714448Active Not Recruiting3,500Est. Mar 2026
NCT00385411Completed81Est. Oct 2008
OD
2 programs
1
1
TopiramatePhase 4
topiramate, phenytoinPhase 3
Novartis
NovartisBASEL, Switzerland
1 program
1
1
TRILEPTAL(oxcarbazepine)Phase 31 trial
Active Trials
NCT00050947Completed94Est. Feb 2004
Bial
BialPortugal - Coronado
34 programs
27
3
3
ESL 800 mgPhase 31 trial
Eslicarbazepine AcetatePhase 31 trial
Eslicarbazepine acetatePhase 31 trial
BIA 2-093Phase 21 trial
BIA 2-093Phase 21 trial
+29 more programs
Active Trials
NCT01532726CompletedEst. Sep 2014
NCT02777671CompletedEst. Dec 2007
NCT01678976CompletedEst. Apr 2002
+31 more trials
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
14 programs
9
4
GWP42003-PPhase 31 trial
GWP42003-PPhase 31 trial
GWP42003-P 20 mg/kg/day DosePhase 31 trial
GWP42003-P 20 mg/kg/day DosePhase 31 trial
CX-8998Phase 21 trial
+9 more programs
Active Trials
NCT02660255Approved For Marketing
NCT03406702Completed7Est. Mar 2019
NCT00594945Completed45Est. Jun 2009
+11 more trials
SK Life Science
SK Life ScienceNJ - Paramus
7 programs
3
4
RWJ-333369Phase 31 trial
RWJ-333369Phase 31 trial
carisbamatePhase 31 trial
carisbamatePhase 31 trial
RWJ 333369Phase 21 trial
+2 more programs
Active Trials
NCT00210522CompletedEst. Jun 2010
NCT00210652CompletedEst. Mar 2010
NCT00616148CompletedEst. Jan 2010
+4 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
1
1
retigabine/ezogabinePhase 31 trial
ezogabine/retigabinePhase 21 trial
Active Trials
NCT01494584Terminated5Est. Apr 2013
NCT01668654Terminated4Est. Jun 2013
Xenon Pharmaceuticals
2 programs
2
XEN496Phase 31 trial
XEN496Phase 31 trial
Active Trials
NCT04912856Terminated8Est. Nov 2023
NCT04639310Terminated8Est. May 2023
Pfizer
PfizerNEW YORK, NY
1 program
1
ICA-105665Phase 21 trial
Active Trials
NCT00979004Terminated13Est. Sep 2010
Healx
HealxUK - Cambridge
1 program
1
TAK-935Phase 2
Takeda
TakedaTOKYO, Japan
1 program
1
TAK-935Phase 23 trials
Active Trials
NCT04992442Completed6Est. Aug 2020
NCT03650452Completed141Est. Jul 2020
NCT02497235Completed11Est. Jan 2016
VP
1 program
1
VX-765 Part APhase 21 trial
Active Trials
NCT01501383Terminated55
PTC Therapeutics
1 program
1
atalurenPhase 21 trial
Active Trials
NCT02758626Completed15Est. Feb 2021
Neurelis
NeurelisCA - San Diego
2 programs
1
1
Diazepam Nasal Spray [Valtoco]Phase 1/21 trial
DiazepamPhase 11 trial
Active Trials
NCT01364558Completed24Est. Apr 2011
NCT05076838Completed35Est. Mar 2025
Biohaven
BiohavenNEW HAVEN, CT
1 program
1
BHV-700Phase 11 trial
Active Trials
NCT07125261RecruitingEst. Sep 2026
UNEEG Medical
UNEEG MedicalDenmark - Allerod
3 programs
24/7 EEG™ SubQ systemN/A1 trial
A minimally-invasive EEG monitoring deviceN/A1 trial
UNEEG EpiSight solutionN/A1 trial
Active Trials
NCT04526418Terminated64Est. Aug 2025
NCT07385157Active Not Recruiting9Est. Mar 2026
NCT05915988Active Not Recruiting19Est. Dec 2026
Design Therapeutics
1 program
eslicarbacepineN/A1 trial
Active Trials
NCT02573272UnknownEst. Oct 2016
Neuroelectrics
NeuroelectricsSpain - Barcelona
1 program
transcranial direct current stimulationN/A1 trial
Active Trials
NCT06334952RecruitingEst. Jan 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
EisaiPerampanel
EisaiPerampanel 1 week titration
EisaiPerampanel Oral Tablet
EisaiPerampanel
Eisaiperampanel
UCB PharmaLevetiracetam
UCB PharmaLevetiracetam
UCB PharmaLacosamide
EisaiZonisamide at targeted daily doses of 100-500 mg/day
EisaiZonisamide
EisaiZonisamide
Eisaizonisamide
UCB PharmaLevetiracetam
Eisaizonisamide
NeuroPaceRNS® System

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 8,716 patients across 50 trials

A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Start: Oct 2022Est. completion: Jan 2025125 patients
Phase 4Completed
NCT04417907EisaiPerampanel 1 week titration

Perampanel Titration and Cognitive Effects

Start: Oct 2021Est. completion: May 202329 patients
Phase 4Terminated
NCT03457129EisaiPerampanel Oral Tablet

Fycompa Titration Intervals and Effects on Retention Rate

Start: Apr 2018Est. completion: Dec 202120 patients
Phase 4Completed

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Start: May 2016Est. completion: Apr 2018106 patients
Phase 4Completed

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

Start: Nov 2015Est. completion: Jul 20178 patients
Phase 4Terminated

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy

Start: Jun 2011Est. completion: Jul 2014353 patients
Phase 4Completed

Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures

Start: Nov 2010Est. completion: May 2015343 patients
Phase 4Completed

Cognitive and Behavioral Effects of Lacosamide

Start: May 2010Est. completion: Dec 201532 patients
Phase 4Completed
NCT01546688EisaiZonisamide at targeted daily doses of 100-500 mg/day

A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures

Start: Nov 2008Est. completion: Aug 201141 patients
Phase 4Terminated

Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate

Start: Jun 2008Est. completion: Apr 20092 patients
Phase 4Completed

ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs

Start: Apr 2008Est. completion: Sep 200932 patients
Phase 4Completed

Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy

Start: Feb 2008Est. completion: Mar 2011121 patients
Phase 4Completed

Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia

Start: Nov 2006Est. completion: Mar 200824 patients
Phase 4Completed

Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation

Start: May 2006Est. completion: Jul 2009200 patients
Phase 4Completed

RNS® System LTT Study

Start: Apr 2006Est. completion: May 2018230 patients
Phase 4Completed
NCT01127165Eisaizonisamide low dose group

Low and High Dose Zonisamide in Children as Monotherapy

Start: Mar 2006Est. completion: Jul 2009125 patients
Phase 4Completed
NCT00385411Sanofivalproate microgranules

Study of Valproate in Young Patients Suffering From Epilepsy

Start: Mar 2006Est. completion: Oct 200881 patients
Phase 4Completed
NCT00312676AbbottRapid versus slow conversion

Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote

Start: Mar 2006Est. completion: Oct 200620 patients
Phase 4Unknown

A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy

Start: Dec 2005Est. completion: Jun 2007409 patients
Phase 4Completed

Open Label, Zonegran (Zonisamide) In Partial Onset Seizures

Start: Oct 20051,000 patients
Phase 4Completed

A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

Start: Sep 2005Est. completion: Dec 2008140 patients
Phase 4Completed

Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization

Start: May 2005Est. completion: Feb 2008157 patients
Phase 4Terminated

Levetiracetam for Benign Rolandic Epilepsy

Start: Mar 2005Est. completion: Sep 20066 patients
Phase 4Completed

Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy

Start: Mar 2003Est. completion: Jul 200414 patients
Phase 4Completed

A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Start: Mar 2003Est. completion: Jul 200435 patients
Phase 4Completed

Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy

Start: Nov 2002Est. completion: Nov 20033 patients
Phase 4Completed

S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

Start: Aug 2000Est. completion: Feb 20041,541 patients
Phase 4Completed
NCT05147571NeuroPaceResponsive stimulation

RNS System NAUTILUS Study

Start: Aug 2022Est. completion: Mar 2026100 patients
Phase 3Active Not Recruiting

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Start: Aug 2021Est. completion: Nov 20238 patients
Phase 3Terminated

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Start: Mar 2021Est. completion: May 20238 patients
Phase 3Terminated

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Start: Mar 2021Est. completion: Jul 203070 patients
Phase 3Recruiting

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Start: Dec 2020Est. completion: Feb 202548 patients
Phase 3Completed
NCT02484001BialESL 800 mg

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

Start: Mar 2016Est. completion: Sep 2018
Phase 3Completed

A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994

Start: Jan 2016Est. completion: Jan 2020106 patients
Phase 3Completed
NCT02408549UCB PharmaLacosamide Tablet

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

Start: Aug 2015Est. completion: Mar 2023239 patients
Phase 3Completed

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Start: Jun 2015Est. completion: May 2016225 patients
Phase 3Completed

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Start: May 2015Est. completion: Nov 20167 patients
Phase 3Completed
NCT02224690Jazz PharmaceuticalsGWP42003-P 20 mg/kg/day Dose

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Start: Apr 2015Est. completion: Mar 2016171 patients
Phase 3Completed

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Start: Apr 2015Est. completion: Apr 2018199 patients
Phase 3Completed
NCT02408523UCB PharmaLacosamide Tablet

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Start: Apr 2015Est. completion: Jun 2019242 patients
Phase 3Completed
NCT02091375Jazz PharmaceuticalsGWP42003-P 20 mg/kg/day Dose

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Start: Mar 2015Est. completion: Nov 2015120 patients
Phase 3Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Start: Aug 2014Est. completion: Apr 2022540 patients
Phase 3Completed

Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures

Start: Jun 2014Est. completion: Dec 20149 patients
Phase 3Completed

A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters

Start: May 2014Est. completion: May 20157 patients
Phase 3Terminated

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Start: Apr 2014Est. completion: Nov 201719 patients
Phase 3Completed

Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU

Start: Nov 2013Est. completion: Aug 201562 patients
Phase 3Completed

Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures

Start: Sep 2013Est. completion: Sep 2015436 patients
Phase 3Completed

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Start: Aug 2013Est. completion: Jan 2017404 patients
Phase 3Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Start: Mar 2013Est. completion: Jul 2019473 patients
Phase 3Completed

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Start: Oct 2012Est. completion: Aug 201626 patients
Phase 3Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

77 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 8,716 patients
26 companies competing in this space